Vistagen Therapeutics, Inc. (VTGN)
$0.26+$0.00 (+1.25%) Today
Reid G. Adler - OfficerVistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 4 | 126,174 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
21 Form 4 filings on record, the earliest from Jun 30, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Douglas J. Williamson - Director | Grant or award | Stock Options (Right to Buy) | 40,826 | $0.00 | - | |
| Reid G. Adler - Officer | Grant or award | Common Stock | 36,818 | $0.19 | $7K | |
| Nick B. Tressler - Officer | Grant or award | Common Stock | 11,712 | $0.19 | $2K | |
| Shawn Singh - Officer | Grant or award | Common Stock | 36,818 | $0.19 | $7K | |
| Angel S. Angelov - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | - | - | |
| Nick B. Tressler - Officer | Grant or award | Incentive Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Shawn Singh - Officer | Grant or award | Incentive Stock Option (right to buy) | 3,732 | $0.00 | - | |
| Shawn Singh - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 71,268 | $0.00 | - | |
| Joshua S. Prince - Officer | Grant or award | Incentive Stock Option (right to buy) | 18,752 | $0.00 | - | |
| Joshua S. Prince - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 56,248 | $0.00 | - | |
 Elissa S. Cote - Officer | Grant or award | Incentive Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Reid G. Adler - Officer | Grant or award | Incentive Stock Option (right to buy) | 18,753 | $0.00 | - | |
| Reid G. Adler - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 56,247 | $0.00 | - | |
| Nick B. Tressler - Officer | Grant or award | Common Stock (Right to Buy) | 150,000 | - | - | |
| Paul R. Edick | Grant or award | Stock Option (Right to Buy) | 35,200 | - | - | |
 Jon S. Saxe - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,600 | $0.00 | - | |
 Margaret M. Fitzpatrick - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,600 | $0.00 | - | |
 Mary L. Rotunno - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,600 | $0.00 | - | |
 Joanne Curley - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,600 | $0.00 | - | |
| Ann Michelle Cunningham - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,600 | $0.00 | - | |
| Reid G. Adler - Officer | Grant or award | Common Stock | 7,541 | $1.70 | $13K | |
| Joshua S. Prince - Officer | Grant or award | Common Stock | 4,882 | $1.70 | $8K | |
 Cynthia Lynn Anderson - Officer | Grant or award | Common Stock | 6,617 | $1.70 | $11K | |
| Shawn Singh - Officer | Grant or award | Common Stock | 7,541 | $1.70 | $13K |
Vistagen Therapeutics, Inc. (VTGN) had 4 insider filings in the last 90 days, with the most recent on 2026-07-31. The full record for VTGN runs to 21 Form 4 filings, the earliest from 2025-06-30. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of VTGN were filed in the last 90 days.
No insider sales of VTGN were filed in the last 90 days.
This page tracks VTGN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VTGN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
